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Available online 27 January 2016Introduction: A variety of radiolabelled minigastrin analogues targeting the cholecystokinin 2 (CCK2) receptor
were developed and compared in a concerted preclinical testing to select the most promising radiotracer for
diagnosis and treatment of medullary thyroid carcinoma (MTC). DOTA–DGlu–DGlu–DGlu–DGlu–DGlu–DGlu–
Ala–Tyr–Gly–Trp–Met–Asp–Phe–NH2 (CP04) after labelling with 111In displayed excellent characteristics, such
as high stability, receptor affinity, specific and persistent tumour uptake and low kidney retention in animal
models. Therefore, it was selected for further clinical evaluation within the ERA-NET project GRAN-T-MTC.
Here we report on the development of a pharmaceutical freeze-dried formulation of the precursor CP04 for a
first multi-centre clinical trial with 111In-CP04 in MTC patients.
Materials and methods: The kit formulation was optimised by adjustment of buffer, additives and radiolabelling
conditions. Three clinical grade batches of a final kit formulation with two different amounts of peptide (10 or
50 μg) were prepared and radiolabelled with 111In. Quality control and stability assays of both the kits and the
resulting radiolabelled compound were performed by HPLC analysis.
Results: Use of ascorbic acid buffer (pH 4.5) allowed freeze-drying of the kit formulation with satisfactory
pellet-formation. Addition of methionine and gentisic acid as well as careful selection of radiolabelling
temperature was required to avoid extensive oxidation of the Met11-residue. Trace metal contamination, in
particular Zn, was found to be a major challenge during the pharmaceutical filling process in particular for the
10 μg formulation. The final formulations contained 10 or 50 μg CP04, 25 mg ascorbic acid, 0.5 mg gentisic acid
and 5 mg L-methionine. The radiolabelling performed by incubation of 200–250 MBq 111InCl3 at 90 °C
for 15 min resulted in reproducible radiochemical purity (RCP) N94%. Kit-stability was proven for N6 months
at +5 °C and at +25 °C. The radiolabelled product was stable for N4 h at +25 °C.
Conclusion: A kit formulation to prepare 111In-CP04 for clinical applicationwas developed, showing high stability
of the kit as well as high RCP of the final product.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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. This is an open access article under1. Introduction
Medullary thyroid carcinoma (MTC) is still one of themost challeng-
ing cancers for both physicians andpatients (Hazard et al., 1959;Miccoli
et al., 2007; Sippel et al., 2008; Machens et al., 2007). Epidemiological
studies have shown that during the past 30 years neither a change in
stage at diagnosis nor improvement in survival has occurred for MTCthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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third of patients present with locally invasive tumours or clinically ap-
parent spread to the regional lymph nodes and 13% with distant meta-
static spread. In particular patients with metastatic MTC are left with
few ineffective therapeutic options. Chemotherapy has been of limited
value, and radiation therapy may be used only to control local disease.
Therefore, it is necessary to develop alternative therapeutic strategies
to control tumour growth, possibly throughmanipulation of various cel-
lular signalling pathways and the use of new biomarkers.
The cholecystokinin 2 (CCK2) receptor is overexpressed inMTCwith
high density and incidence of over 90%, as revealed by autoradiographic
studies (Reubi and Waser, 2003; Béhé and Behr, 2002). From the late
1990's, a variety of CCK2/gastrin related peptides (members of the gas-
trin and cholecystokinin families, or possessing such characteristics)
were studied in vitro and in preclinical animal models. First generation
of radiolabelled minigastrins, based on human minigastrin (Leu–Glu–
Glu–Glu–Glu–Glu–Ala–Tyr–Gly–Trp–Met–Asp–Phe–NH2) were associated
with very high uptake and retention in the kidneys (von Guggenberg
et al., 2004). Truncation of the sequence by removal of amino terminal
Glu-residues resulted in lower kidney uptake, but metabolic stability
was severely compromised (Good et al., 2008). In a multi-centre
preclinical study within a coordinated research project (COST BM0607)
a number of different minigastrin analogues conjugated with 1,4,7,10-
tetraazacyclododecane-N,N′,N″,N‴-tetraacetic acid (DOTA) and suitable
for radiolabelling with 111In, 68Ga (for diagnostic imaging), or with 90Y
and 177Lu (for radionuclide therapy) were compared with respect to sta-
bility (Ocak et al., 2011), receptor binding, internalisation (Aloj et al.,
2011), in vivo tumour targeting and pharmacokinetics in animal models
(Laverman et al., 2011). From this comparison 111In-DOTA–DGlu–DGlu–
DGlu–DGlu–DGlu–DGlu–Ala–Tyr–Gly–Trp–Met–Asp–Phe–NH2 (111In-
CP04) showed the most promising characteristics for clinical translation,
such as high metabolic stability, receptor affinity, high and prolonged tu-
mour uptake and low kidney retention (Kolenc Peitl et al., 2015) (see Fig.
1). As a result, 111In-CP04 was selected for further clinical evaluation in
MTC-patients, currently being implemented within the frameworks of a
multinational European cooperation project on personalised medicine
(TRANSCAN call of the EU within ERA-NET, project GRAN-T-MTC). The
aim of the project is to evaluate the safety and tumour-targeting efficacy
of 111In-CP04 in patients with metastatic MTC. For the first-in-human
study two dosage forms were required: a lower dose containing 10 μg
CP04 and a higher dose of 50 μg CP04, both to be radiolabelled with
200–250 MBq 111In for patient application. The 10 μg dose is intended
to be used in first applications of 111In-CP04. Only if safety is ensured
the 50 μg dose will be applied, an amount of precursor also suitable
for later translation towards radionuclide therapy by radiolabelling
with e.g. 177Lu.
For conducting a clinical trial in Europe, a pharmaceutical dossier,
named Investigational Medicinal Product Dossier (IMPD, based onFig. 1. Structure of 111In-labelled DOTA–DGlu–DGlu–DGlu–DGlu–DGlu–DGlu–Ala–Tyr–Gly–Trpthe common technical dossier (CTD) format) has to be submitted, con-
taining extensive chemical and pharmaceutical data on the compound
concerned aswell as information of pre-clinical pharmacology, pharma-
cokinetics and toxicology in animal models. For radiopharmaceuticals
special information related to radioactivity and radiolabelling properties
has to be provided (Todde et al., 2014). Herein we report on the chem-
ical and pharmaceutical development and characterisation of a freeze-
dried kit formulation for radiolabelling of the radiopharmaceutical pre-
cursor CP04with 111In (chapter 2.1 of theCTD). Data on preclinical phar-
macology, pharmacokinetics and toxicology (chapter 2.2. of the CTD)
will be reported separately.2. Material and methods
2.1. Chemicals and materials
If not otherwise stated, chemicals, materials and solvents were of
pharmaceutical grade for kit preparation and reagent grade for other
experiments and were used without further purification.
111InCl3 solution was supplied by Mallinckrodt Pharmaceuticals
(Petten, NL) as a sterile, non-pyrogenic solution of non-carrier-
added 111InCl3 in 0.05 M HCl. Each 0.5 mL of the solution contained
185 MBq (5 mCi) of 111InCl3 at time of calibration (specific activity
of N1.85 GBq/μg indium at time of calibration).
L-Methionine was provided by SAFC chemicals (Cleveland, OH) in
pharmaceutical grade, ascorbic acid (pharmaceutical grade) and
gentisic acid (Ultrapure quality) were provided by Sigma Aldrich
(St. Louis, MO).
Sterilised distilled water for injection (Pharm.Eur.) was provided by
Fresenius Kabi (Halden, Norway) in 10 mL plastic ampoules.
For freeze-drying, 2- or 10-mL clear borosilicate glass vials from
SCHOTT (StandardLine, FIOLAX®, Müllheim, Germany) corresponding
to Ph.Eur. Type I, with chlorobutyl rubber stoppers were used.2.2. CP04-precursor
CP04 was synthesised by piCHEM (Graz, Austria) in GMP grade.
Briefly, Fmoc solid phase peptide synthesis (SPPS) was applied by
the use of a batch-mode synthesiser. Cleavage from the resin and
deprotection of side chain functionalities were performed in one step
using trifluoroacetic acid (TFA), followed by preparative RP-HPLC
purification. Tri-t-Bu-DOTA was coupled in solution to the peptide,
deprotected by TFA and again HPLC purified, followed by freeze-
drying and filling into Sterile Square Media Bottles (PETG). Analytical
testing includedmass spectrometry, amino acid analysis, purity, content
of peptide, water, TFA and residual solvents and endotoxins.–Met–Asp–Phe–NH2 (CP04), sum formula: C89H118N19O35S111In, MW (av) 2157.1 g/mol.
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2.3.1. HPLC-analysis
HPLC-system 1 (CP04 quantification and kit quality control): LC-
10 AD pumps (Shimadzu), with a variable wavelength detector SPD-
10A, oven CTO 10AS (Shimadzu), manual injector Rheodyne 1725
with a 20 μL loop, column: Kinetex C18, 5 μm, 150 mm × 4.6 mm
(PhenomenexTorrance, CA); flow rates of 1 mL/min; temperature:
40 °C, UV detection at 220 nm; isocratic elution (25% of 0.1% TFA
(explained already above) in acetonitrile (ACN) and 75% of 0.1%
aq.TFA). Quantification of CP04 in kits was achieved with the aid
of a standard curve using CP04 CRS standard with peptide content
established by elemental analysis, whereby specificity, linearity, range,
accuracy, precision, limit of detection (LOD) and quantitation (LOQ)
were determined.
HPLC-system 2 (impurity characterisation and radiochemical
purity determination): UltiMate 3000 autosampler with an UltiMate
3000 variable wavelength detector (Dionex, Thermo Scientific,
Germering, Germany) and RayTest GABI radioactivity detector
(Raytest, Straubenhard, Germany), column: Kinetex C18, 5 μm,
150 mm × 4.6 mm (Phenomenex); flow rates of 1 mL/min; UV detec-
tion at 280 nm; isocratic elution; solvents: 25% of 0.1% TFA in ACN and
75% of 0.1% aq. TFA.
Endotoxin testing was performed by Gel Clot technique
using a E. coli 055:B6 endotoxin standard control (Charles River,
Charleston, SC).
Sterility testing was performed according to the European
Pharmacopoeia using the direct inoculation technique.
2.4. Nano-HPLC–ESI-MS analysis
For determination of CP04 impurities in the kit formulations
nano-HPLC electrospray ionisation mass spectrometry (ESI-MS) was
carried out using an UltiMate 3000 nano-HPLC system coupled to a
LTQ Orbitrap XL mass spectrometer (both Thermo Scientific) equipped
with a nanospray ionisation source. The analytes were separated
on a homemade fritless fused-silica microcapillary column (75 μm
i.d. × 280 μm o.d. × 10 cm length) packed with 3 μm reversed-phase
C18 material (Reprosil). Solvents for HPLC were 0.1% formic acid
(solvent A) and 0.1% formic acid in 85% ACN (solvent B). The gradient
profile was as follows: 0–2 min, 4% B; 2–40 min, 4–40% B; 40–45 min,
40–100% B, and 45–55 min, 100% B. The flow rate was 250 nL/min.
The mass spectrometer was operated in the data dependent mode
selecting the top 4 most abundant isotope patterns with charge 2+,
3+, and 4+ from the survey scan with an isolation window of 2
mass-to-charge ratio (m/z). Survey full scan MS spectra were acquired
form 300 to 2000 m/z at a resolution of 60,000.
To characterise the chromatographic behaviour indium, copper (II),
zinc and iron (II) complexes of CP04 were prepared. For this purpose,
50 μg CP04 were incubated with 10-fold molar excess of the respective
chloride salt in ascorbic acid buffer (pH 4.5) followed by brief incuba-
tion at 90 °C for 10 min and subsequently analysed by HPLC system 1.
2.5. Wet-radiolabelling/preformulation studies
Freshly prepared stock solutions of the CP04 peptide were prepared
(100 μg CP04 in 100 μL PBS). 10–20 μL CP04 stock solution and [111In]-
chloride (60 μL, 40–50MBq in 0.02MHCl, pH 1)was buffered by adding
either 100 μL of ascorbic acid buffer (50mgbuffer in 0.2mLH2O, pH3.5)
or 100 μL of sodium acetate buffer (0.8 M, pH 4.5). The incubation
process requires slightly acidic conditions for optimal radionuclide
binding to the DOTA-conjugated peptide. In order to minimise the
Met11 oxidation during radiolabelling, seleno-DL-methionine (10 μL
0.01 mg/μL) was added to the samples. To determine the optimal
reaction conditions, the labelling mixture was incubated between
15 and 30 min at 75/85/95 °C (see Table 1). After incubation, 80 μL ofH2O and 80 μL 0.01 M ethylenediaminetetraacetic acid (EDTA) solution
were added to 20 μL of the radiolabelled mixture. To determine
radiochemical yield (RCY) and radiochemical purity (RCP) of the
radiolabelled product and to monitor the presence of oxidised peptide,
RP-HPLC was carried out (HPLC system 1).
2.6. Kit preparation
19 different development batches (batch no. 1–8) of CP04 kits were
prepared varying different parameters including: CP04 content (10, 20,
50 μg), ascorbic acid content, additives (L-methionine, gentisic acid),
vial size, as summarised in Table 2. After development, 4 batches
(batch no. 9–10) were prepared under GMP conditions meeting
requirements for use in humans and tested extensively regarding all
defined specifications.
The bulk solution of the formulation was prepared in a clean room
using pre-sterilised glass vials, containers and stoppers. To a 250 mL
plastic bottle 2.5 g of ascorbic acid was added, dissolved in 94 mL of
water for injection. The pH of the bulk solution was adjusted to 4.5
with 1 mL of 30% NaOH. Next, 53 mg of gentisic acid and 520 mg of
L-methionine were added and the solution was purged with nitrogen
for 20 min. CP04 (1 mg or 5 mg) was dissolved in 5 mL of 0.1% NaOH
and added to the bulk solution. The final bulk solution was then purged
with nitrogen for 5min and filtered through a 0.2 μmSterifix Paed filter.
The bulk solution was dispensed into the 2 mL or 10 mL vials in the
range of 1mL±1% per vial and the vials were cappedwith the stoppers
and allowed to freeze for 20 h at−70 °C in the freeze-dryer. Afterwards
the product was lyophilised according to the following lyophilisation
scheme: initial shelf temperature was set at −50 °C. During the first
phase of lyophilisation a stable temperature of −38 °C and a pressure
of 0.1 mbar were maintained. Further steps relied on temperature
change from −35 °C to −25 °C at 2.5 °C/h, then the temperature was
changed from −25 °C to 40 °C at 5.0 °C/h. During the second phase of
lyophilisation the product was dried at 40 °C for 8 h. All steps were
conducted at 0.1 mbar pressure. Finally, the freeze-dryer chamber was
filled with sterile and dry nitrogen and, using the mechanic system
of the freeze-dryer, the vials were sealed with rubber stoppers, taken
out of the freeze-dryer and capped with metal caps. The vials were
inspected for container closure defects and product appearance.
Samples were sent to quality control for product release testing.
Quality control of the kit included appearance of kit, water content
by Karl-Fischer coulometric oven method (Metrohm) and appearance
after dissolution in water (1 mL, clarity according to Ph.Eur. 2.2.1.,
colouration according to Ph.Eur. 2.2.2), identification, and quantification
of CP04 by RP-HPLC analysis and detection at 220 nm, measurement of
pH, sterility testing, detection of endotoxins and assessment of RCP after
kit reconstitution and radiolabelling with 111In using RP-HPLC analysis
and radiometric detection.
2.7. Kit radiolabelling
Radiolabelling of CP04 with 111In was carried out in a final volume
of 1 mL. The suitable volume of water was calculated depending on
the radioactivity concentration of the 111In-solution from the provider.
Typically 0.6–0.8 mL of water together with 0.2–0.4 mL of 111InCl3
(200–250 MBq) were rapidly added to the vial. The labelling mixture
was then incubated for 10–30 min at 75–95 °C.
The radiolabelled kit solution was analysed by RP-HPLC. Samples for
analysis were prepared by adding about 20 μL of labelling solution to
100 μL of 0.1 mg/mL DTPA Na3Ca ∙H2O in water, serving as a free 111In
scavenger to prevent sticking of radioactivity on the column.
2.8. Stability studies
The final formulation of both dosages (10 μg: batches 5C, 8B, 9B;
50 μg: batches 8A, 9A) underwent extensive stability testing during
Table 1
Summary of initial 111In-labelling experiments: influence of buffers, incubation times and incubation temperatures on radiochemical purity. (Radiolabelling: 20 μg CP04, 50 MBq 111In).
Buffer solution Incubation time [min] Temperature [°C] Free 111In [%] Oxidised CP04 [%] 111In-labelled CP04 [%]
Ascorbic acid buffer (50 mg/0.2 mL H2O) 15 75 4.3 1.7 93.6
30 75 1.3 3.5 94.4
15 85 11.5 6.6 78.3
30 85 6.2 8.1 81.7
15 95 2.2 8.5 84.9
30 95 2.2 10.2 81.8
Sodium acetate buffer 0.8 M/Se-Met (0.01 mg/μL) 15 75 1.4 1.4 93.8
30 75 1.3 1.5 93.7
15 85 0.5 5.5 90.3
30 85 0.6 5.7 89.4
Sodium acetate buffer (0.8 M) 15 75 0.6 3.8 92.6
30 75 0.6 5.1 91.2
15 85 17.7 2.4 79.0
30 85 17.1 3.5 78.2
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tightly closed with rubber stopper and aluminium seal up to 1 year. In
addition accelerated stability testing at 25 °C for 6 months (batches
8A, 8B, 9A and 9B) was performed. Analytical tests included appearance
before and after dissolution, measurement of pH, radiolabelling with
111In and subsequent HPLC analysis for confirmation of identity and
RCP of 111In-CP04.
Stability of the radiolabelled product was tested for the same kit
batches reported above by determination of RCP by HPLC at different
time points (0, 2, 4 and 24 h) after radiolabelling.
3. Results
3.1. Wet radiolabelling/preformulation studies
Radiolabelling of the precursor CP04 could be performed at high
specific activities (N50 MBq 111In/20 μg CP04) and overall with high
radiochemical yield. An incubation temperature of 75 °C led to RCP
for 111In-labelled CP04 of N90% in all buffer systems. A prolongation
of the incubation time generally resulted in higher oxidation
of Met11 in CP04. Oxidation of the peptide could be reduced
to b1.5% by addition of seleno-DL-methionine in the acetate bufferTable 2
Overview of all CP04 kit batches including production details and main QC-results (Nd = not
Production details
Batch
no.
CP04 stated
content [μg]
Batch size
[number of vials]
Ascorbic
acid [mg]
Methionine
[μg]
Gentisic
acid
1A 10 15 50 0 0
1B 10 15 60 0 0
1C 50 15 75 0 0
2A 10 15 50 0 0
2B 10 15 75 0 0
2C 50 15 75 0 0
3A 10 15 25 0 0
3B 10 15 50 0 0
3C 50 15 25 0 0
4 10 20 25 0 0
5A 10 25 25 0 0
5B 20 25 25 0 0
5C 10 25 25 5.2 0.53
6A 10 50 25 5.2 0.53
6B 10 50 25 5.2 0.53
7A 10 50 25 5.2 0.53
7B 50 50 25 5.2 0.53
8A 50 50 25 5.2 0.53
8B 10 50 25 5.2 0.53
9A (GMP) 50 100 25 5.2 0.53
9B (GMP) 10 100 25 5.2 0.53
10A (GMP) 50 44 25 5.2 0.53
10B (GMP) 10 44 25 5.2 0.53formulation. However, this composition did not achieve signifi-
cantly higher RCP as compared to the ascorbic acid formulation.
Therefore, the ascorbic acid formulation was selected for further
kit development.
3.2. Characterisation of radiochemical impurities
Characterisation of impurities was achieved by HPLC and radiomet-
ric detection (HPLC system 1) with the aid of suitable radioactive
control samples, such as 111InCl3, 111In-DTPA and 111In-CP04 artificially
oxidised by treatment with a diluted H2O2-solution. The respective
retention times (tR) were: “free” 111In (111In-chloride solution
and 111In-DTPA): tR 1.4 min, oxidised 111In-CP04: tR 3.1 min (with 2
visible peaks corresponding to the sulfoxide and the sulfone of the
Met11-residue), 111In-CP04: tR 9.0 min. The identity of oxidised species
was additionally confirmed by identification of the unlabelled oxidised
CP04 at tR 3.1 min by mass spectrometry.
Additional small peaks were detected eluting closely to peaks visible
in the UV trace of the CP04 precursor solutions, thus indicating impuri-
ties from CP04 synthesis. In the final batches of CP04 these radioactive
peaks were always b1% and therefore were not further characterised.
A sample radiochromatogram is shown in Fig. 2.determined).
Quality control results
Vial size
[mL]
CP04 content
measured [μg] (UV)
Intact CP04
[%] (UV)
RCP
[%]
Free
111In [%]
Oxidised
111In-CP04 [%]
10 mL 7.5 63.6 4.4 95.6 0
10 mL 6.8 64.2 Nd Nd Nd
10 mL 6.6 64.3 10.3 89.7 0
10 mL 10.2 54.6 28.3 70.6 1.1
10 mL 9.4 67.2 67.8 26.8 5.4
10 mL 52.3 91.8 91.7 3.6 4.5
10 mL 8.0 70.3 88.2 1.4 10.4
10 mL 8.0 61.8 81.6 8.2 10.2
10 mL 41.9 91.7 92.4 0.8 6.8
10 mL 11.3 19.2 55.7 40.9 3.4
2 mL 12.5 97.0 93.9 0.3 5.8
2 mL 25.0 97.9 94.4 0.3 5.3
2 mL 11.0 90.4 97.7 0.4 1.9
10 mL 12.9 52.4 86.1 Nd Nd
10 mL 14.1 56.5 63.2 36.8 0
10 mL 12.5 35.8 49.3 Nd Nd
10 mL 59.6 84.4 b5 Nd Nd
2 mL 71.2 98.2 98.0 0.5 1.5
2 mL 10.7 97.00 98.3 0.4 1.3
2 mL 44.6 95.3 96.1 0.7 3.2
2 mL 9.3 91.7 96.5 0.7 2.8
2 mL 44.8 96.5 96.7 0.3 3.0
2 mL 9.0 92.2 96.4 0.3 3.2
Fig. 2.HPLC chromatogramof 111In-CP04: sample radiolabelling of kit #9A (system1) radioactivity detection), tR 1.4min: free 111In and 111In-DTPA, tR3.1min: two oxidised forms of 111In-
CP04, tR 9.0 min: 111In-CP04, overall radiochemical purity of the preparation N95%.
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By dissolving the kits in 1mLmetal-free water and analysing the so-
lution by HPLC (system 2) during the development process additional
UV peaks (tR 11.5 min) eluting close to CP04 (tR 10.5 min) were detect-
ed in varying amount (Fig. 3a). The higher the ratio of these unknown
peaks over CP04 the lower the obtained radiolabelling yields were,
especially in the 10 μg formulation.
This phenomenon was attributed to trace-metal contamination
during preparation of the kit and interference with radiolabelling due
to the very low amount of CP04 used. To test this hypothesis, authentic
samples of CP04 complexed with various metals were prepared and
their HPLC profile determined. These complexes eluted with different
retention times, as shown in Fig. 3a (e.g., “free” CP04 10.5 min,
In-CP04 8.5 min, Cu-CP04 10.8 min, Fe-CP04 11.3 min, Zn-CP04
11.5 min). In addition, LC–ESI-MS analysis was performed in one
research batch, revealing Zn-CP04 as the main impurity on HPLC
(Fig. 3b: mass + 62 as compared to “free” CP04 and characteristic
isotope distribution for the Zn-complex).3.4. Kit formulation development
Table 2 summarises the results from all produced kit batches.
Only batches 5C, 8, 9 and 10 resulted in sufficiently high RCP after
radiolabelling the low dose (10 μg) formulation. Initial batches (1–4)
showed high amounts of free 111In, whereby labelling of high dose
(50 μg) kits resulted in RCP of N90% in two cases (batch 2C and 3C).
Additionally, variable levels of oxidised 111In-CP04 — between 1.0 and
10.5% — were found. In batch 5C L-methionine and gentisic acid was
added and compared with the same formulation without these addi-
tives (batch 5A and 5B), showing the amount of oxidised 111In-CP04
considerably reduced from N5 to 1.9%. However, the same formulation
failed to provide high RCP in subsequent batches (6 and 7). Further-
more, after identification of Zn-contamination during the formulation
process (most likely introduced during the washing process of 10 mL
vials), 2 mL vials were used leading to higher RCP values (N95%) in
the final formulation (batches 8, 9 and 10). Given that no significant
influence was seen on RCP by varying the amount of ascorbic acid
(25–75 mg), the lower amount was chosen for the final formulation.
The batches of the final formulation (Table 3) showed very
comparable results at both low dose (10 μg) and high dose (50 μg)
formulations in 4 subsequent batches (Table 4).3.5. Master batch data
Five GMP, clinical grade kit batches (9A, 9B, 10A, 10B, 11) were
tested 3 times for all specifications. Data are summarised in Table 4.
All kits were sterile and revealed low levels of endotoxins, appearance
dissolution and pH were according to specifications. Residual water
was between 2.7 and 3.1%. HPLC analysis revealed intact, non-oxidised
or metal bound CP04 within 10% of the stated amount and RCP
exceeded 95% in all tests. Overall all batches passed release testing.
3.6. Stability studies
Kits with the final kit composition (No. 5, 8 and 9, Table 3)
were radiolabelled after different storage times and the results are
summarised in Table 5. All samples showed no changes in pH,
appearance or CP04 content and RCP values exceeded 95%, except
for one sample which was stored at 25 °C for 3 months with a RCP
value of 94.8%. No significant trend towards lower RCP values or
new radiochemical impurities at longer storage times were detected.
Additional parameters, such as appearance before and after
dissolution, or pH did not show any undesirable changes within the
observation period.
Test results on the stability of the radiolabelled products are shown
in Table 6. Up to 4 h after labelling no significant change in RCP was
detected and only after 24 h a trend towards lower RCP was seen,
although very limited with RCP values of N94%. Additional tests also
revealed no decrease in RCP values during storage in the vial or in syrin-
ges over a period of 4 h and no indication of adsorption on the wall of
syringes or vials (data not shown).
4. Discussion
The development of a radiotracer from the research phase into a
clinically applicable (radio)pharmaceutical for first-in-human clinical
trials is a challenging task (Reilly et al., 2015) and needs to abide to
particular guidelines as compared to “conventional” drugs. It should
be taken into account that a kit formulation, as presented here, is not
used as such in patients, but only serves as a platform for the on-site
preparation of the actual radiopharmaceutical. The addition of a radio-
nuclide precursor (111In-chloride) solution to a kit following a pre-
defined procedure will yield the final radiopharmaceutical for intrave-
nous injection to patients. Accordingly, the development of such kit
formulation is primarily focused on ensuring the successful performance
Fig. 3. a. Top chromatograms: UV trace (280 nm) during HPLC analysis (system 2) of standards of CP04 (red) and different metal complexes thereof (indium, copper, iron and
zinc). Lower chromatograms: UV-trace (280 nm) of kit samples dissolved in metal free water, blue and red traces represent 10 μg kit batches, green and black 50 μg kit
batches with added RCP values after radiolabelling of different vials of the same batch (red and black poor, blue and green good radiolabelling, corresponding to the presence
of a second peak) b: Identification of corresponding Zn-complex in kit # 2 associated with A, as shown in comparative mass spectra of the main CP04 peak (top, HPLC-
tR10.5 min) and the Zn-complex (bottom, HPLC-tR 11.5 min) with a mass addition of 62 Da and characteristic isotopic distribution of Zn.
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Table 3
Final kit composition.
Names of ingredients Amount Function Quality requirements
CP04.TFA salt (DOTA–DGlu–DGlu–DGlu–DGlu–DGlu–DGlu–
Ala–Tyr–Gly–Trp–Met–Asp–Phe–NH2)
10 μg or 50 μg Active substance GMP certification
L-Ascorbic acid 25 mg Excipient antioxidant, stabiliser Pharmaceutical grade
Gentisic acid 0.53 mg Excipient antioxidant In house specification
L-Methionine 5.2 mg Excipient antioxidant, stabiliser Pharmaceutical grade
Sodium hydroxide 3.9 mg Excipient for pH adjustment Pharmaceutical grade
Nitrogen q.s. Protective gas 99.9999 vol%
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radiolabelled drug, rather than on testing the kit before radiolabelling,
to safeguard the efficacy of the radiopharmaceutical.
In this particular case, a peptide-ligand targeting CCK2 receptors and
modified with a chelator to bind a radiometal, here 111In, had to be
formulated to ensure almost quantitative binding of the radiometal.
In general, for radiopharmaceuticals the unlabelled (non-radioactive)
precursor should not saturate the target to comply with the so-called
tracer principle (Konijnenberg et al., 2014). In the present formulation
intended for the use in a first-in-human study, a very low amount of
CP04 (the precursor) was chosen to be administered in patients.
For safety reasons the study will be initiated starting with only 10 μg
CP04 (4.9 nmol), which is the active substance in the formulation
(Committee for human medical products (CHMP), 2008). A second
higher dose (50 μg) formulation has also been included for use in a
subsequent phase of this clinical trial (Decristoforo et al., 2015).
This very small amount of peptide is highly challenging to handle.
Although comparable formulations are on themarket, e.g., Octreoscan®
(Summary of Product characteristics Octreoscan, 2004), very little detail
is reported in the literature for radiolabelling of freeze-dried peptide-
conjugates with trivalent metals intended for molecular targetingTable 4
Master batch data of GMP produced clinical grade kit batches (all data mean of N = 3).
1.) 10 μg formulation
Test Specification
Appearance White freeze-dried solid
Appearance after dissolution in 1 mL of water
for injection
Clear, colourless or slightly yellow
Identification of CP04 From 95 to 105% of retention time
CP04 standard
Assay of CP04 8 –12 μg
Radiochemical purity (after radiolabelling
with 220 MBq of 111In)
≥90%
≤5% free 111In
≤5% 111In-CP04ox
pH after dissolution in 1 mL of water for injection 4.0–5.0
Sterility Passes sterility test
Bacterial endotoxins b20 EU/kit
2.) 50 μg formulation
Test Specification
Appearance White freeze-dried solid
Appearance after dissolution in 1 mL of water
for injection
Clear, colourless or slightly ye
Identification of CP04 From 95 to 105% of retention
CP04 standard
Assay of CP04 40 –54 μg
Radiochemical purity (after radiolabelling
with 220 MBq of 111In)
≥ 90%
≤5% free 111In
≤5% 111In-CP04ox
pH after dissolution in 1 mL of water for injection 4.0–5.0
Sterility Passes sterility test
Bacterial endotoxins b20 EU/kitapplications. The amount of the DOTA-conjugated peptide is much
lower than in comparable formulations of antibodies or small proteins,
that have been reported for 111In-labelling (Scollard et al., 2011; Reilly
et al., 2004). Another difference is that the described kit formulations
use DTPA as chelator for 111In, whereas in this case DOTA is used. To
our knowledge this is the first report on a freeze-dried kit formulation
of a DOTA-conjugated peptide. DOTA is known to form stable com-
plexes with a variety of metals, such as copper, zinc or ferric ions, that
are frequently present in the environment and easily introduced during
the formulation process and interfere with radiolabelling (Breeman
et al., 2003). Last but not least, CP04 contains the oxidation-prone
Met11 residue in the receptor-binding site of the peptide chain, which
upon oxidation leads to complete loss of CCK2-receptor affinity and
thus total loss of its targeting efficacy (von Guggenberg et al., 2009).
These challenges could be positively addressed step-by-step in the
present work, as described in more detail below.
4.1. Preformulation
Although the sodium acetate buffer with seleno-DL-methionine
showed high RCP, it has limitations for kit formulation development.Batch
5C/14 8B/14 9B/14 10B/14
Complies Complies Complies Complies
solution Complies Complies Complies Complies
of the Complies Complies Complies Complies
11.0 μg 10.7 μg 9.3 μg 9.0 μg
97.7%
0.4%
1.9%
98.3%
0.4%
1.3%
96.5%
0.7%
2.8%
96.4%
0.3%
3.3%
4.5 4.5 4.5 4.5
Passes Passes Passes Passes
b1.25 EU/kit b1.25 EU/kit b1.25 EU/kit b0.25 EU/kit
Batch
8A/14 9A/14 10A/14
Complies Complies Complies
llow solution Complies Complies Complies
time of the Complies Complies Complies
– 44.6 μg 44.8 μg
98.0%
0.5%
1.5%
96.1%
0.7%
3.2%
96.7%
0.3%
3.0%
4.5 4.5 4.5
Passes Passes Passes
b1.25 EU/kit b1.25 EU/kit b0.25 EU/kit
Table 5
Long termandaccelerated stability data of differentbatches of the CP04 kits (Radiochemical
purity after radiolabelling with 111In (nd = not determined/analysed).
Time Storage 5 °C ± 3 °C Storage 25 °C
(“accelerated”)
Batch 5 8 9 8 9
10 μg formulation Release 97.7 97.6 96.1 97.6 96.1
1 month nd nd nd 97.1 95.7
3 months 96.7 96.5 95.7 96.5 94.8
6 months 97.0 97.8 96.1 95.9 95.3
9 months nd 96.3 nd nd nd
12 months nd nd 95.9 nd nd
50 μg formulation Release nd 97.4 95.6 97.4 95.6
1 month nd nd nd 97.1 96.1
3 months nd 97.0 96.1 97.5 95.1
6 months nd 96.9 96.0 97.1 92.9
9 months nd 96.7 nd nd nd
12 months nd nd 95.2 nd nd
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intravenously, whereas an acetate buffer formulation cannot be freeze-
dried and may have limitations regarding stability. Based on that,
an ascorbic acid formulation (de Blois et al., 2012) was chosen instead
for further kit development.
4.2. Kit development and impurities
19 development freeze-dried batches were prepared to finally come
to a suitable kit formulation. The major parameters were successfully
addressed, resulting in a suitable product for clinical application.
A low amount of ascorbic acid of 25 mg was sufficient, given that a
higher content did not improve radiopharmaceutical quality but only
increased the risk of trace-metal contamination. A detailed investigation
on the composition of the radiopharmaceutical precursor in the kit
was required to identify the source of trace-metal contaminants. The
presence of Zn-CP04 by-product was clearly identified by LC–MS, both
by the mass and by the isotopic profile in the MS signal. Although the
exact source of Zn contamination was not found, e.g., metal removal
in the water used by ion exchange resin did not improve the result,
the problem could be eventually resolved by a combination of actions,
such as changing of container size from 10 to 2 mL, general use of low
metal containing solutions and non-metallic instruments during the
washing process. In particular, the careful selection of coated containers
ensured no detectable adsorption of peptide on the glass surface, the
amount of precursor was within 10% of the predicted value. Test mea-
suring the residual activity after withdrawing the radiolabelled
solution into syringes confirmed this (b5% remaining radioactivity).
Addition of methionine and gentisic acid as antioxidants (de Blois
et al., 2012) increased RCP up to N95% mainly due to the suppression
of Met11-oxidation of the CP04 precursor. These anti-oxidants also re-
sulted in excellent stability of both the kit and the radiolabelled product.
The formulation was successfully translated to four subsequent
GMP/clinical grade batches of CP04 kits for 111In-labelling, passing
all predefined quality control tests both related to the kit itself (pH,
appearance, sterility, endotoxins, CP04 content), as well as related to
the radiolabelling step (RCP).Table 6
Stability data of 111In-CP04 preparations from kits (Radiochemical purity at indicated
time points).
Batch
no.
CP04
content [μg]
After
radiolabelling
2 h post
preparation
4 h post
preparation
24 h post
preparation
5C 10 96.7 97.5 97.1 95.9
8A 50 97.1 97.1 97.0 96.8
8B 10 97.1 97.1 97.1 96.8
9A 50 95.6 95.6 95.6 95.0
9B 10 96.1 95.4 95.4 94.44.3. Stability
The described final formulation (Table 4) showed excellent
radiolabelling yield and radiochemical purity after storing the kits
up to 1 year in a refrigerator (5 °C) or up to 6 months at 25 °C
(Table 5). Therefore, the shelf life has been set to 1 year thus far.
However, results from ongoing tests may potentially extend storage
times. In view of the fact that no degradation in quality has been
registered up to now, it is likely that much longer shelf lives will finally
be defined.Moreover, stability of the radiolabelled product in solution is
excellent in the current formulation, considering the resistance of
the peptide to oxidation, the absence of quality deterioration as long
as 4 h after labelling and the only minimal decrease in purity 24 h
after labelling.
Overall this data indicates compliance of the described formulation
with the requirements for radiopharmaceutical preparations, as outlined
in the respective guidelines of the European Medicines Agency
(Committee for human medical products (CHMP), 2008). Further
experiments to reproduce these findings in a therapeutic setting by
switching the radionuclide from 111In to the β-emitter 177Lu are un-
derway. So far the described formulation has passed the evaluation
process by the pharmaceutical (“competent”) authorities and ethical
committees in three participating European countries, while three appli-
cations are pending.
5. Conclusion
A promising drug candidate, a radiopeptide targeting the
CCK2 receptor initially intended for a first-in-man diagnostic and
dosimetric study, was successfully developed into a kit formulation
for radiolabelling with 111In, whereas data on preclinical pharma-
cology, dosimetry and toxicity testing will be reported separately.
The described formulation will be used in a first multi-centre clin-
ical trial inMTCpatientswith the aim to contribute to the improvement
of the diagnosis and therapy of metastatic MTC.
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